Dexamethasone inhibits paclitaxel-induced cytotoxic activity through retinoblastoma protein dephosphorylation in non-small cell lung cancer cells

International Journal of Oncology

Volumn 30, Issue 1, 2007, Pages 187-192

  Morita, Masato ^a   Suyama, Hisashi ^a   Igishi, Tadashi ^a   Shigeoka, Yasushi ^a   Kodani, Masahiro ^a   Hashimoto, Kiyoshi ^a   Takeda, Kenichi ^a   Sumikawa, Takashi ^a   Shimizu, Eiji ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Dexamethasone; Non small cell lung cancer; Paclitaxel; Retinoblastoma

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; DEXAMETHASONE; DNA; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; PACLITAXEL; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; KINETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; DEXAMETHASONE; DNA, NEOPLASM; ENZYME INHIBITORS; HUMANS; KINETICS; LUNG NEOPLASMS; MORPHOLINES; PACLITAXEL; RETINOBLASTOMA PROTEIN;

EID: 39049183664     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.1.187     Document Type: Article

References (33)

1. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
2. Crino L: Combined platinum containing treatment in NSCLC. Lung Cancer 38 (suppl. 3): S51-S52, 2002.
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
4. Manfredi JJ, Parness J and Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94: 688-696, 1982.
5. Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263-1268, 1990.
6. Gennari A, Salvadori B, Tognoni A and Conte PF: Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 7: 978-979, 1996.
7. Quock J, Dea G, Tanaka M, Gandara D, Lara P and Lau D: Premedication strategy for weekly paclitaxel. Cancer Invest 20: 666-672, 2002.
8. Rogatsky I, Trowbridge JM and Garabedian MJ: Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Mol Cell Biol 17: 3181-3193, 1997.
9. Sanchez I, Goya L, Vallerga AK and Firestone GL: Glucocorticoids reversibly arrest rat hepatoma cell growth by inducing an early G1 block in cell cycle progression. Cell Growth Differ 4: 215-225, 1993.
10. Corroyer S, Nabeyrat E and Clement A: Involvement of the cell cycle inhibitor CIP1/WAF1 in lung alveolar epithelial cell growth arrest induced by glucocorticoids. Endocrinology 138: 3677-3685, 1997.
11. Ramalingam A, Hirai A and Thompson EA: Glucocorticoid inhibition of fibroblast proliferation and regulation of the cyclin kinase inhibitor p21Cip1. Mol Endocrinol 11: 577-586, 1997.
12. Baghdassarian N, Catallo R, Mahly MA, et al: Glucocorticoids induce G1 as well as S-phase lengthening in normal human stimulated lymphocytes: differential effects on cell cycle regulatory proteins. Exp Cell Res 240: 263-273, 1998.
13. Rogatsky I, Hittelman AB, Pearce D and Garabedian MJ: Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids. Mol Cell Biol 19: 5036-5049, 1999.
14. Mihara K, Cao XR, Yen A, et al: Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246: 1300-1303, 1989.
15. Shimizu E, Coxon A, Otterson GA, et al: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9: 2441-2448, 1994.
16. Harbour JW and Dean DC: Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2: E65-E67, 2000.
17. Suyama H, Igishi T, Sano H, et al: ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol 24: 1499-1504, 2004.
18. Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S and Uehara Y: Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15: 629-637, 1997.
19. Lenferink AE, Busse D, Flanagan WM, Yakes FM and Arteaga CL: ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 61: 6583-6591, 2001.
20. Brennan P, Babbage JW, Burgering BM, Groner B, Reif K and Cantrell DA: Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7: 679-689, 1997.
21. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC and Testa JR: The phosphatidylinositol 3-kinase/ AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60: 5390-5394, 2000.
22. MacKeigan JP, Collins TS and Ting JP: MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 275: 38953-38956, 2000.
23. Seidman R, Gitelman I, Sagi O, Horwitz SB and Wolfson M: The role of ERK 1/2 and p38 MAP-kinase pathways in taxolinduced apoptosis in human ovarian carcinoma cells. Exp Cell Res 268: 84-92, 2001.
24. MacKeigan JP, Taxman DJ, Hunter D, Earp HS III, Graves LM and Ting JP: Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 8: 2091-2099, 2002.
25. Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092, 2002.
26. Shingu T, Yamada K, Hara N, et al: Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 63: 4044-4047, 2003.
27. Bacus SS, Gudkov AV, Lowe M, et al: Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20: 147-155, 2001.
28. Peyssonnaux C and Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93: 53-62, 2001.
29. Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676, 2004.
30. Tsuruo T, Naito M, Tomida A, et al: Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94: 15-21, 2003.
31. Osada H and Takahashi T: Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21: 7421-7434, 2002.
32. Hidalgo M, Aylesworth C, Hammond LA, et al: Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol 19: 2493-2503, 2001.
33. Gradishar WJ, Tjulandin S, Davidson N, et al: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803, 2005.